Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform

被引:18
作者
Agtini, M. D.
Ochiai, R. L.
Soeharno, R.
Lee, H. J.
Sundoro, J.
Hadinegoro, S. R.
Han, O. P.
Tana, L.
Halim, F. X. S.
Ghani, L.
Delima
Lestari, W.
Sintawati, F. X.
Kusumawardani, N.
Malik, R.
Santoso, T. S.
Nadjib, M.
Soeroso, S.
Wangsasaputra, F.
Ali, M.
Ivanoff, B.
Galindo, C. M.
Pang, T.
Clemens, J. D.
Suwandono, A.
Acosta, C. J. [1 ]
机构
[1] Int Vaccine Inst, Seoul, South Korea
[2] Minist Hlth, Communicable Dis Control & Environm Hlth, Jakarta, Indonesia
[3] Natl Inst Hlth Res & Dev, Jakarta, Indonesia
[4] Univ Indonesia, Ctr Hlth Res, Jakarta, Indonesia
[5] Minist Hlth, Infect Dis Hosp, Jakarta, Indonesia
[6] WHO, Vaccines & Other Biol, CH-1211 Geneva, Switzerland
[7] WHO, Res Policy & Cooperat, CH-1211 Geneva, Switzerland
关键词
mass vaccination; typhoid fever; typhoid vi vaccine; Indonesia;
D O I
10.1016/j.puhe.2006.06.008
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: To report results on coverage, safety and logistics of a large-scale, school-based Vi polysaccharide immunization campaign in North Jakarta. Methods: Of 443 primary schools in North Jakarta, Indonesia, 18 public schools were randomly selected for this study. Exclusion criteria were fever 37.5 degrees C or higher at the time of vaccination or a known history of hypersensitivity to any vaccine. Adverse events were monitored and recorded for 1 month after immunization. Because this was a pilot programme, resource use was tracked in detail. Results: During the February 2004 vaccination campaign, 4828 students were immunized (91% of the target population); another 394 students (7%) were vaccinated during mop-up programmes. Informed consent was obtained for 98% of the target population. In all, 34 adverse events were reported, corresponding to seven events per 1000 doses injected; none was serious. The manufacturer recommended cold chain was maintained throughout the programme. Conclusions: This demonstration project in two sub-districts of North Jakarta shows that a large-scale, school-based typhoid fever Vi polysaccharide vaccination campaign is logistically feasible, safe and minimally disruptive to regular school activities, when used in the context of an existing successful immunization platform. The project had high parental acceptance. Nonetheless, policy-relevant questions still need to be answered before implementing a widespread Vi polysaccharide vaccine programme in Indonesia. (c) 2006 The Royal Institute of Public Health. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1081 / 1087
页数:7
相关论文
共 17 条
[1]   A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design [J].
Acosta, CJ ;
Galindo, CM ;
Ali, M ;
Abu Elyazeed, R ;
Ochiai, RL ;
Danovaro-Holliday, MC ;
Page, AL ;
Thiem, VD ;
Jin, Y ;
Park, JK ;
Lee, H ;
Puri, MK ;
Ivanoff, B ;
Agtini, MD ;
Soeharno, R ;
Simanjuntak, CH ;
Punjabi, NH ;
Canh, DG ;
Sur, D ;
Nizami, Q ;
Manna, B ;
Dong, BQ ;
Anh, DD ;
Yang, HH ;
Bhattacharya, SK ;
Bhutta, Z ;
Trach, DD ;
Xu, ZY ;
Pang, TK ;
Donner, A ;
Clemens, JD .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2005, 10 (12) :1219-1228
[2]   Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up [J].
Acosta, CJ ;
Yang, HH ;
Wang, N ;
Gao, Q ;
Deng, Q ;
Ma, XL ;
Zhou, BD ;
Wei, L ;
Danovaro-Holliday, MC ;
Ochiai, RL ;
Wang, XY ;
Kim, DR ;
Xu, ZY ;
Dong, BQ ;
Galindo, CM ;
Clemens, JD .
VACCINE, 2005, 23 (48-49) :5618-5623
[3]  
Acosta CJ, 2004, J HEALTH POPUL NUTR, V22, P240
[4]   Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002 [J].
Begier, EM ;
Burwen, DR ;
Haber, P ;
Ball, R .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (06) :771-779
[5]   Evaluation of a new Vi polysaccharide typhoid vaccine in children aged 2-5 years (Reprinted from Journal of Pediatrics, vol 48, pg 85-88, 1999) [J].
Cordero-Yap, L ;
Rivera, RG ;
Dispo, AP ;
Mallabo, J .
BIODRUGS, 2001, 15 (Suppl 1) :27-27
[6]   Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia [J].
DeRoeck, D ;
Clemens, JD ;
Nyamete, A ;
Mahoney, RT .
VACCINE, 2005, 23 (21) :2762-2774
[7]  
*GLAX INC, 2002, PROD MON
[8]   Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization [J].
Klugman, KP ;
Koornhof, HJ ;
Robbins, JB ;
LeCam, NN .
VACCINE, 1996, 14 (05) :435-438
[9]  
KOSEN S, UNPUB STUDY SAFETY I
[10]  
*MIN HLTH IND, 2001, NAT LEV 5 YEAR STRAT